Showing results (261-270 of 2,509) with videos related to

Sort By:
Pageof 251
Clinical Lymphoma, Myeloma & Leukemia|September 6, 2011
Ribosomal protein metallopanstimulin-1 impairs multiple myeloma CAG cells growth and inhibits fibroblast growth factor receptor 3Yuemeng Dai, Spencer Pierson, Cross Dudney, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 11, 2011
Reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma: a concise reviewRachel B Salit, Michael R Bishop
Clinical Lymphoma, Myeloma & Leukemia|June 11, 2011
High-dose therapy/autologous hematopoietic stem cell transplantation in relapsed or refractory marginal zone non-Hodgkin lymphomaLanfang Li, Philip Bierman, Julie Vose, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 11, 2011
Late afternoon dosing of plerixafor for stem cell mobilization: a practical solutionDennis L Cooper, Kathryn Pratt, Julie Baker, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 11, 2011
External validation of newly proposed cytogenetic risk classification in patients who have myelodysplastic syndrome: a retrospective analysis at a single institutionJina Yun, Dong Hwan Kim, Jee Hyun Kong, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 1, 2011
Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failureA Megan Cornelison, Hagop Kantarjian, Jorge Cortes, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 1, 2011
Dasatinib combined with interferon-alfa induces a complete cytogenetic response and major molecular response in a patient with chronic myelogenous leukemia harboring the T315I BCR-ABL1 mutationA Megan Cornelison, Mary-Alma Welch, Charles Koller, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 1, 2011
Targeting the bone marrow in Waldenstrom macroglobulinemiaIrene M Ghobrial, Yong Zhang, Yang Liu, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 1, 2011
Non-Hodgkin's lymphoma: the old and the newFernando Cabanillas
Clinical Lymphoma, Myeloma & Leukemia|July 7, 2011
Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II studyAaron D Schimmer, Wolfgang Herr, Mathias Hänel, et al.
Pageof 251